- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
QuantifEYE Program detects AMD risk
St. Louis-ZeaVision LLC's QuantifEYE Program quickly, conveniently, and inexpensively identifies potential risk of age-related macular degeneration (AMD) and other diseases of the eye.
St. Louis-ZeaVision LLC's QuantifEYE Program quickly, conveniently, and inexpensively identifies potential risk of age-related macular degeneration (AMD) and other diseases of the eye. The device measures pigment in the macula (i.e., low macular pigment has been associated with high risk for AMD.)
Previously only available at research facilities, the program now allows physicians to screen patients at an early age and can monitor patient's macular pigment optical density levels as part of an eye-care routine, according to the company.
The QuantifEYE Program is only available in the St. Louis market, but ZeaVision hopes to expand nationally and into key European markets in 2007.
